Astera Labs (NASDAQ:ALAB) Downgraded by Northland Securities to Market Perform

Astera Labs (NASDAQ:ALAB) was downgraded by investment analysts at Northland Securities from an “outperform” rating to a “market perform” rating in a report released on Friday, Marketbeat.com reports.

ALAB has been the topic of several other research reports. Royal Bank Of Canada lifted their price objective on Astera Labs from $425.00 to $500.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Barclays boosted their price target on shares of Astera Labs from $200.00 to $325.00 and gave the company an “equal weight” rating in a research report on Monday, July 20th. Needham & Company LLC increased their price objective on Astera Labs from $260.00 to $425.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Susquehanna lifted their target price on shares of Astera Labs from $230.00 to $275.00 and gave the company a “neutral” rating in a report on Friday, July 31st. Finally, TD Cowen lowered their price target on Astera Labs from $425.00 to $375.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. Ten equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $348.33.

Astera Labs Price Performance

ALAB stock opened at $347.05 on Friday. The firm has a 50 day simple moving average of $316.82 and a two-hundred day simple moving average of $290.03. The stock has a market cap of $60.21 billion, a PE ratio of 171.81 and a beta of 3.68. Astera Labs has a one year low of $97.89 and a one year high of $499.48.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.11. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The company had revenue of $392.40 million during the quarter, compared to the consensus estimate of $360.85 million. During the same period in the previous year, the firm posted $0.44 EPS. The firm’s revenue was up 104.5% compared to the same quarter last year. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. On average, research analysts expect that Astera Labs will post 2.7 EPS for the current fiscal year.

Insider Activity at Astera Labs

In related news, COO Sanjay Gajendra sold 90,630 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $340.35, for a total value of $30,845,920.50. Following the sale, the chief operating officer owned 1,119,038 shares in the company, valued at approximately $380,864,583.30. The trade was a 7.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Philip Mazzara sold 6,801 shares of Astera Labs stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $340.50, for a total value of $2,315,740.50. Following the completion of the transaction, the general counsel owned 96,542 shares of the company’s stock, valued at approximately $32,872,551. This trade represents a 6.58% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 396,059 shares of company stock valued at $122,605,660 in the last 90 days. 10.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Astera Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in ALAB. Greenleaf Trust boosted its stake in shares of Astera Labs by 1.8% in the second quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock worth $966,000 after acquiring an additional 36 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in shares of Astera Labs by 74.5% during the 2nd quarter. Parkside Financial Bank & Trust now owns 96 shares of the company’s stock valued at $46,000 after acquiring an additional 41 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in shares of Astera Labs by 2.7% during the 1st quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock worth $209,000 after buying an additional 51 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new position in shares of Astera Labs in the 2nd quarter valued at $25,000. Finally, Integrated Wealth Concepts LLC increased its position in shares of Astera Labs by 0.7% during the second quarter. Integrated Wealth Concepts LLC now owns 7,006 shares of the company’s stock valued at $3,384,000 after acquiring an additional 52 shares during the last quarter. Institutional investors own 60.47% of the company’s stock.

About Astera Labs

Astera Labs, Inc is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help data centers connect and manage processors, memory, storage, and networking components in high-performance computing systems.

The company’s portfolio includes Aries PCI Express and Compute Express Link (CXL) smart memory controllers, Scorpio PCIe switches, Taurus Ethernet fabric switches, and Leo CXL memory connectivity products.